MedTrace Logo

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

NCT00623974 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2012-12-06

Study results available
· View outcomes & findings →

Summary

Primary Objective:

-To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck, mediastinal lymph node neck dissections), with which serum calcium will be raised to corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end of the treatment course.

Conditions

Interventions

DRUG

Teriparatide (Forteo)

Subcutaneous Injection Every 12 Hours for 7 Days

DRUG

Calcium

1000 milligrams by mouth (PO) Every 12 Hours

DRUG

Calcitriol

0.25 micrograms PO Every 12 Hours

Sponsors & Collaborators

Principal Investigators

  • Mimi Hu, MD · UT MD Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623974 on ClinicalTrials.gov